Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Recruiting in Palo Alto (17 mi)
+19 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Cyclacel Pharmaceuticals, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
Research Team
CB
Chandra Belani, M.D.
Principal Investigator
Milton S. Hershey Medical Center
Eligibility Criteria
Inclusion Criteria
Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
Must have measurable disease according to RECIST
Eastern Cooperative Oncology Group performance status 0-1
See 4 more
Treatment Details
Interventions
- Seliciclib (Cyclin-Dependent Kinase Inhibitor)
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: Arm 1 with seliciclibActive Control1 Intervention
Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
Group II: Arm 2 with placebo controlPlacebo Group1 Intervention
Randomized to placebo after run-in period.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
New Mexico Oncology Hematology ConsultantsAlbuquerque, NM
Arizona Cancer CenterTucson, AZ
University of Pittsburg Cancer InstitutePittsburgh, PA
University of Maryland, Greenebaun Cancer CenterBaltimore, MD
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Cyclacel Pharmaceuticals, Inc.
Lead Sponsor
Trials
20
Patients Recruited
2,100+